| Entries |
| Document | Title | Date |
|---|
| 20080206360 | Folate based migraine treatment - Formulations for the prevention and treatment of headaches, particularly migraine headaches, comprise folate in combination with one or more of riboflavin, feverfew, or an extract of feverfew, magnesium in the form of acid salts, magnesium oxide, complexes or chelates and/or other nutritional supplements such as vitamin B6, B12, betaine, and plant derived phytochemicals or synthesized versions thereof. | 08-28-2008 |
| 20080220094 | Compositions and methods for the treatment and/or prevention of osteoporosis - The invention of this application relates to compositions and methods for the treatment and/or prevention of osteoporosis; improving and/or enhancing bone formation; and prevention and/or reducing bone mineral density loss. More particularly, the invention relates to a composition comprising vitamin K, in any form and betacryptoxanthin. A further aspect of this invention is a composition comprising vitamin K, in any form, betacryptoxanthin, and/or vitamin D and/or calcium. | 09-11-2008 |
| 20080241278 | SEROTONIN AND CATECHOLAMINE SYSTEM SEGMENT OPTIMIZATION TECHNOLOGY - A method of treating neurotransmitter dysfunction in a patient. The method includes the step of administering an amino acid precursor of a catecholamine in a balanced and effective therapeutic range. The catecholamine precursor is preferably L-dopa, but may alternatively be tyrosine, D,L-Phenylalanine or an active isomer thereof, and N-acetyl-L-tyrosine or other amino acid precursor of L-dopa. An amino acid precursor of serotonin in an effective therapeutic range, is also administered. The serotonin precursor is preferably 5-HTP, but may alternatively be tryptophan. At least one cofactor is also preferably administered. Cofactor options include Vitamin B6, Vitamin C, Calcium, Folate, and Cysteine. A method of periodic administration and patient checking is also disclosed. | 10-02-2008 |
| 20080241279 | Materials and methods of using calcium for reduction of inflammation - Nutritional approaches for the control of inflammation can involve the administration of therapeutic amounts of calcium. The administration of appropriate amounts of calcium to an individual results in a reduction in inflammatory processes and markers associated with the inflammatory processes. The therapeutic amount of calcium can be selected to change a level of inflammation in the individual. The approach for reducing inflammation can comprise a step of measuring the C-reactive protein marker level and administering calcium in amounts selected to induce a change in the C-reactive protein level. The calcium can be incorporated into a product with corresponding instructions to induce a desired inflammation reduction. | 10-02-2008 |
| 20080268070 | Skin Care Cream Containing Baked Shell Powder and Method of Manufacturing the Same - A skin care cream can exert strengthened anti-bacterial effects and effects of curing athlete's foot, miliaria, freckles and other skin diseases for a prolonged period of time. The skin care cream is prepared by adding baked powder of highly calcium-containing shells such as dead shells or pearls to and mixing them with a raw material for manufacturing cosmetic cream. Preferably, dead shells are baked at temperature between 1,000 and 1,300° C. Preferably, unbaked shell powder is further added to and mixed with a raw material for manufacturing cosmetic cream. | 10-30-2008 |
| 20080299225 | STABLE MICROBICIDAL COMPOSITION - A microbicidal composition contains isothiazolone compounds, which contain 5-chloro-2-methyl-4-isothiazolin-3-one and 2-methyl-4-isothiazolin-3-one, a nitrate in a content of 3% by weight to 25% by weight with respect to a total weight of the composition, a haloacetamide in a content of 5 ppm to 500 ppm, and water. A nitrate in a proportion of 3% by weight to 25% by weight and a haloacetamide in a proportion of 5 ppm to 500 ppm are added to an aqueous solution of isothiazolone compounds, which contain 5-chloro-2-methyl-4-isothiazolin-3-one and 2-methyl-4-isothiazolin-3-one. | 12-04-2008 |
| 20080305186 | Method and Composition for the Treatment of Cardiac Hypertrophy - The present invention includes compositions and methods treat a patient suffering from one or more symptoms of cardiac hypertrophy, hypertension and/or ischemia by administering a pharmaceutically effective amount of a pharmaceutical composition having an anti-epileptic drug and an antibiotic to the patient, for example, the anti-epileptic drug may be carbamazepine and the antibiotic may be doxycycline. | 12-11-2008 |
| 20080305187 | Use of Parathyroid Hormone for Treating Periodontal Disease and for Other Dental Applications - Method for treating or preventing periodontal disease associated with mild to severe alveolar bone loss, and for improving the prognosis of dental implant procedures by administering human parathyroid hormone to a patient in need thereof. | 12-11-2008 |
| 20080311225 | Process and Kit for Formation of Active Hydrogen Water, Gypsum Feeder for the Formation, Active Hydrogen Forming Materials and Process for the Production of the Materials - An active hydrogen-dissolved water generator | 12-18-2008 |
| 20080317872 | Final Finish Aftershave - The irritation experienced by many males resulting from shaving with a razor and/or a depilatory has been well documented. There are several causes, the most outstanding being the tendency of the clipped hair to curl and grow inward beneath the skin surface. The shaved surface then bumps as the combined result of shaving irritation and clipped hairs which have not grown straight through the skin. | 12-25-2008 |
| 20090022817 | METHODS OF MODIFYING MYOCARDIAL INFARCTION EXPANSION - A bioscaffolding can be formed within a post-myocardial infarct region sufficient to cause attenuation of a rate of myocardial infarct expansion. A bioscaffolding may further be formed in the post-myocardial infarct region to cause an increase in posterior left ventricular wall thickness. The gel or bioscaffolding can be formed from a mixture of gel components of different gelation systems. For example, a bioscaffolding can be formed by mixing at least two different components of at least two different two-component gelation systems to form a first mixture and by mixing at least two different components (other than the components that make up the first mixture) of the at least two different two-component gelation systems to form a second mixture. | 01-22-2009 |
| 20090041861 | ESTROGEN RECEPTOR ALLELES THAT ARE PREDICTIVE OF INCREASED SUSCEPTIBILITY TO BONE FRACTURE - In one aspect, the present invention provides methods of determining susceptibility to bone fracture in a mammalian subject, wherein the methods comprise analyzing nucleic acid molecules obtained from the mammalian subject to determine which of the P, p X, and x alleles of the estrogen receptor α gene are present, wherein the presence of a haplotype comprising the p and x alleles is indicative of an increased susceptibility to bone fracture. The present invention also provides kits for determining susceptibility to bone fracture in a mammalian subject. | 02-12-2009 |
| 20090068289 | FORMULATION FOR MENOPAUSAL WOMEN - The present disclosure relates to novel compositions which provide improved nutritional support for premenopausal and menopausal women and/or relief from systems associated with menopause, as well as prophylactic effects, and methods for using same. | 03-12-2009 |
| 20090074886 | GSK-3 INHIBITORS - This invention relates to methods of treating or preventing bone loss by administering to a human or animal subject pyrimidine and pyridine derivatives that inhibit the activity of glycogen synthase kinase 3 (GSK3), to pharmaceutical compositions containing the compounds, and to the use of the compounds and compositions alone or in combination with other pharmaceutically active agents. | 03-19-2009 |
| 20090130231 | PHARMACEUTICAL FORMULATION FOR TREATING TINEA OF FEET AND HANDS AND PREPARATION THEREOF - A pharmaceutical formulation for treating tinea of feet and hands is disclosed, which is composed of Fructus Gleditsia, Alumen and Borneol. Also disclosed is a cream preparative method of the pharmaceutical formulation, which comprises Fructus Gleditsia is decocted with water, and the decocted liquid is dried under decompression into powder, which is formulated to a cream together with the powders of Alumen and Borneol as well as the respective excipients. | 05-21-2009 |
| 20090181109 | Nanoveson.TM.: treatment, biomarkers and diagnostic tests for liver diseases and comorbid diseases - A method of treatment of liver diseases and comorbid diseases is disclosed wherein an oral dose of lipids in an amount effective to trigger the release of cholecystokinin (CCK) into the duodenum to generate a major release of bile phospholipids from remodeled stores of triglycerides (TAG) in the liver, is administered to a patient in need thereof, thereby causing the formation of sequestered and aggregated mixed micelles and vesicles (SAMMVs) in the intestines of the patient which are then eliminated via the bowels of the patient. | 07-16-2009 |
| 20090238898 | METHOD OF INHIBITING THE PROLIFERATION AND MIGRATION OF HELICOBACTOR PYLORI - strains are indigenous to each human host and infect and colonize in the stomach of the host, and they are also known to be involved in diseases of the upper gastrointestinal tracts, among others. The present invention provides an economical method for inhibiting the proliferation and migration of | 09-24-2009 |
| 20090258091 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES - The present invention relates to compositions and methods for treating neurodegenerative diseases. In some embodiments, the present invention provides compositions for treating and preventing presbycusis. | 10-15-2009 |
| 20090263507 | BIOLOGICAL MARKERS AND RESPONSE TO TREATMENT FOR PAIN, INFLAMMATION, NEURONAL OR VASCULAR INJURY AND METHODS OF USE - The invention provides methods and kits for treatment of pain, inflammation, neuronal or vascular injury and the use of biomarkers for the assessment of the biological activity or disease state. In one embodiment, the kit comprises a biomembrane sealing agent, such as PEG, a bioactive agent, such as a magnesium compound, and an assay for measuring a biomarker. The biomarker is measured pre-, mid- and post-treatment, and results of the measurements are compared to evaluate the treatment, treatment regimen and outcomes. | 10-22-2009 |
| 20090285909 | Lactate and Calcium Containing Pharmaceutical Composition and Uses Thereof - The invention relates to a pharmaceutical composition containing 250 to 5000 millimoles per liter of lactate or lactic acid, 0.5 to 1.99 millimoles per liter of calcium and optionally 2 to 10 millimoles per liter of potassium. The invention also relates to pharmaceutical uses of this composition. | 11-19-2009 |
| 20090324748 | TRAUMA THERAPY - The invention provides a method of reducing injury to cells, tissues or organs of a body following trauma by administering a composition to the body following trauma, including: (i) a potassium channel opener or agonist and/or an adenosine receptor agonist; and (ii) a local anaesthetic. Also provided is a composition for reducing injury to cells, tissues or organs of a body following trauma including: (i) and (ii). The composition may be hypertonic. | 12-31-2009 |
| 20100086625 | METHODS FOR TREATING SKIN LESIONS - The present invention relates to the treatment of skin lesions such as cold sores and other complications resulting from disorders such as herpes and the like. The invention relates to the use of a composition comprising one or more aluminum salts for treatment purposes. | 04-08-2010 |
| 20100092580 | Weight Reducing Composition - The invention relates to soft drink industry, in particular, to dietetic nutrition. The inventive weight reducing composition comprises 0.01-10 mg/l of sodium and 25-150 mg/l of magnesium, the rest being water. Said composition (drinking water) makes it possible to reduce weight without altering the usual eating habits. In addition, consumption of said drinking water results in reduction of weight by 1.2-2.9 kg. | 04-15-2010 |
| 20100178363 | AGENT FOR PREVENTING BLEEDING FROM CEREBRAL CORTICAL VEIN - The present invention provides: a superficial cerebral vascular bleeding inhibitor comprising an aqueous solution containing 120 to 160 mEq/L of sodium ion, 1 to 5 mEq/L of calcium ion, and 75 to 165 mEq/L of chloride ion; the superficial cerebral vascular bleeding inhibitor further comprising 1 to 5 mEq/L of potassium ion; and a packaged container containing the superficial cerebral vascular bleeding inhibitor (with or without potassium ion). The superficial cerebral vascular bleeding inhibitor of the present invention can effectively prevent or inhibit bleeding from superficial cerebral blood vessels in the field of neurosurgery such as intracranial surgery and the like, thereby capable of securing a clear operating field during intracranial surgery and inhibiting the occurrence of post-surgery damage. | 07-15-2010 |
| 20100183747 | BODY FLUID EXPANDERS COMPRISING N-SUBSTITUTED AMINOSULFONIC ACID BUFFERS - A buffered body fluid expander solution, in which the buffer is a physiologically acceptable buffer that is not an inorganic phosphate buffer, comprises calcium ions and magnesium ions at a concentration ratio of 5:1 to 1:1. The non-phosphate buffer may be a physiologically acceptable N-substituted aminosulfonic acid buffers, especially those having a pKa value in aqueous solution of from 7.1 to 7.5 at 2O0C, and most preferably N-tris(hydroxymethyl) methyl-2-aminoethanesulfonic acid (TES), 3-(N-morpholino) propanesulfonic acid (MOPS), N,N-bis(2-hydroxyethyl)-2-aminoethanesulfonic acid (BES) and combinations thereof. Preferred components include from 100 to 150 (preferably about 135) mmoles/L sodium ions, from 2.5 to 6.2 (preferably about 5) mmoles/L potassium ions, from 0.1 to 2.5 (preferably about 1.25) mmoles/L calcium ions, from 0.4 to 25.0 (preferably about 0.45) mmoles/L magnesium ions, from 96 to 126 (preferably about 118) mmoles/L chloride ions, 2 to 11 mmoles/L (preferably about 10) glucose (preferably D-glucose), from 50 to 150 (preferably about 110) μmoles/L glycerol, from 7 to 15 (preferably about 10) μmoles/L choline, from 5 to 400 (preferably about 300) μmoles/L glutamate (preferably L-glutamate), from 5 to 200 (preferably about 20) μmoles/L aspartate (preferably L-aspartate), from 100 to 2000 (preferably about 400) μmoles/L glutamine (preferably L-glutamine), from 15 to 215 (preferably about 60) μmoles/L pyroglutamate, from 20 to 200 (preferably about 100) μmoles/L arginine (preferably L-arginine), from 1 to 120 (preferably about 40) nmoles/L thiamine pyrophosphate (TPP), from 40 to 70 (preferably about 50) μmoles/L D- or DL or L-carnitine (preferably L-carnitine), and from 5 to 200 (preferably about 28) ml.U./L porcine or human insulin (preferably human insulin). The solutions are useful for the manufacture of medicaments and blood volume expanders, for treating hypovolemia or for treating the loss of extracellular and interstitial fluid in subjects suffering with burns, for treating respiratory and/or metabolic acidosis in a subject, for perfusion of the abdominal cavity during peritoneal dialysis of a subject with acute renal failure or an acute toxicity condition, for preventing and/or ameliorating reperfusion injury, and for delivering a therapeutic, test and/or synergistic agent to a subject, including a biological agent, such as at least one stem cell, peptide or genomic derived protein. | 07-22-2010 |
| 20100196514 | CALCIUM SILICATE-BASED COMPOSITE CEMENT AND METHODS FOR THE PREPARATION - The present invention provides a method for producing calcium silicate-based bone cement and a composition produced by the method. It further provides a novel composition for bone tissue repair. | 08-05-2010 |
| 20100203168 | Bone microenvironment modulated seizure treatments - Novel etiology underlying certain types of seizures is presented, whereby changes in endocrine levels result in changes in osteoclast activity levels which in turn result in elevated extracellular Ca2+ levels which in turn result in systemic alterations in nerves, including increased membrane depolarization and enhanced neurotransmitter release, which in turn result in increased seizure risk in people with low seizure thresholds. Treatment methods are provided that modulate the bone microenvironment to provide an etiology based seizure treatment method based on the novel disclosures. The treatment methods include use of compounds such as calcitonin, SERMs such as raloxifene, testosterone, estrogen, calcimimetics such as cinacalcet, RANKL inhibitors such as denosumab, and bisphosphonates such as risedronate. | 08-12-2010 |
| 20100203169 | Composition and Method of Treating Side Effects From Antibiotic Treatment - A method of treating side effects of antibiotic treatment includes the step of internally administering an antibiotic that is capable of inducing hearing loss in a mammal. The method further includes the step of internally administering a composition to the mammal in conjunction with administration of the antibiotic. The composition includes a biologically effective amount of at least one scavenger of singlet oxygen, vitamin E, vitamin C, and a vasodilator comprising magnesium. The combination of vitamins and the vasodilator comprising magnesium, in the biologically effective amounts, provides an effective treatment for treating side effects of antibiotic treatment. | 08-12-2010 |
| 20100209541 | BUCCAL, POLAR AND NON-POLAR SPRAY OR CAPSULE CONTAINING DRUGS FOR TREATING METABOLIC DISORDERS - Buccal aerosol sprays or capsules using polar and non-polar solvent have now been developed which provide biologically active compounds for rapid absorption through the oral mucosa, resulting in fast onset of effect. The buccal polar compositions of the invention comprise formulation I: aqueous polar solvent, active compound, and optional flavoring agent; formulation II: aqueous polar solvent, active compound, optionally flavoring agent, and propellant; formulation III: non-polar solvent, active compound, and optional flavoring agent; and formulation IV: non-polar solvent, active compound, optional flavoring agent, and propellant. | 08-19-2010 |
| 20100233296 | METHOD AND SYSTEM FOR PRODUCING A SUBSTANCE OR A SIGNAL WITH A COAGULATING OR ANTICOAGULANT EFFECT - The invention concerns a method and a system for producing a signal, in particular an electric signal, or a substance having a coagulating or anticoagulant effect. The method is characterised in that it is based on a source substance with coagulating effect, in particular, Ca | 09-16-2010 |
| 20100239689 | METHOD OF INHIBITING ALVEOLAR BONE RESORPTION AND PERIODONTAL MEMBRANE LOSS AND COMPOSITION FOR INTERNAL USE TO BE USED THEREIN - Alveolar bone resorption, periodontal membrane loss, and gingival recession can be inhibited by administering 500 mg to 2000 mg per day of calcium, 10 mg to 40 mg per day of soy isoflavone aglycone, and vitamin D | 09-23-2010 |
| 20100247676 | COMPOSITIONS AND METHODS FOR TREATMENT OF HEMORRHAGE - Methods of treating hemorrhage are provided, comprising diagnosing one or more hemorrhaging or potentially hemorrhaging vessels in a patient and administering to the patient a therapeutically effective amount of a composition comprising a vessel closing compound at a concentration between about 0.1% and about 45%. The vessel closing compound may comprise a polymer with hydrophilic properties, such as polyethylene glycol (PEG). The composition may also comprise one or more active agent such as a blood flow modifier with a potential to form ionic bonds with the vessel closing agent. | 09-30-2010 |
| 20100247677 | Compositions and Methods for Preferential Distribution of Active Agents to Injury Sites - Compositions are provided for preferential distribution of active agents to injury sites. Such compositions may comprise a ligand with hydrophilic properties and one or more active agents, such as compounds comprising hydrophilic metal ions. Because the delivery ligand and the active agent are specifically selected so the interactions between them are mainly of an ionic nature so that binding of the active agent to the delivery ligand and release of the active agent into the target site are not dependent on enzymatic activity. Methods of using such compositions are also disclosed. | 09-30-2010 |
| 20100285152 | COMPOSITION FOR IMPROVING LIVER METABOLISM AND DIAGNOSTIC METHOD - There is a need to develop a treatment for metabolic syndrome, which is directed to maintaining healthy liver metabolism and not indirectly through weight loss. The present invention provides a composition comprising whey protein for supporting and improving liver metabolism, especially in connection with fatty liver. The composition can further comprise Ca and health improving components such as probiotics and prebiotics. The composition can be in the form of food, health food, food supplement or drugs. Furthermore, due to the complexity of choice of a valid biomarker and sample matrix, there is a special need to find out specific biomarkers for fatty liver and metabolic syndrome. This invention also relates to a diagnostic method for determining fatty liver on the basis of metabolomic profiling. Statistical modelling methods are used on the metabolomic profiles to identify the biomarkers. | 11-11-2010 |
| 20100316735 | COMPOSITIONS AND METHODS FOR REDUCING HANGOVER SYMPTOMS - Compositions and methods for reducing hangover symptoms. Generally, a hangover reducing composition includes one or more plant extracts, such as prickly pear cactus extract, white willow bark extract, milk thistle extract, green tea extract, and combinations thereof. In some cases, the composition further includes supplemental nutrients, such as vitamins and minerals (including electrolytes). Some examples of suitable nutrients include sodium, potassium, magnesium, and vitamins C, B1, B2, B3, B6, and B12. The composition is administered to a person in any suitable form, including as a carbonated soft drink, an energy drink, a tea, a sports drink, a non-carbonated drink, a pill, an elixir, and so forth. In some preferred instances, the composition is formulated as a carbonated soft drink. In order to reduce hangover symptoms, the composition is ingested before, during, and/or after the consumption of a drug, such as alcohol. | 12-16-2010 |
| 20110027391 | LIQUID NUCLEOTIDES/NUCLEOSIDES-CONTAINING PRODUCT - The invention pertains to a liquid composition for preventing and/or treating memory decline and/or cognitive dysfunction, Alzheimer's, Parkinson's and/or dementia, said composition comprising: (i) at least 50 mg nucleoside and/or nucleotide per 100 ml; (ii) between 0.2 and 10 grams protein per 100 ml; (iii) between 0.05 and 3 wt. % of 5 thickener, based on total weight of the composition. The thickener is preferably selected from the group consisting of cellulose, xanthan gum, gellan gum, alginate, guar gum, locust bean gum, gum karaya, gum tragacanth, carrageenan, and mixtures thereof. The composition preferably has a loss factor tan δ between 0.1 and 100, as measured at any strain in the range of 1 100% at 0.1 Hz and 20° C. It is particularly found that a thickener selected from the group consisting of gellan gum, xanthan gum and cellulose greatly reduces sedimentation. | 02-03-2011 |
| 20110038954 | CALCIUM-RICH ALKALINE POWER PRODUCED FROM PROCESSED MOLLUSC SHELLS - A calcium-rich powder possessing therapeutic properties produced by washing and sterilising the shells of molluscs taken from an uncontaminated marine environment, heating said washed and sterilised shells to a temperature of between 1000° C. and 2000° C. for a period of at least 10 hours, reducing the temperature of the resultant material to room ambient temperature over a period of at least 24 hours, and then crushing said resultant material to a fine powder. | 02-17-2011 |
| 20110059188 | COMPOSITIONS FOR REDUCING DENTAL EROSION - The present invention relates to the use of a protein selected from one or more of casein, ovalbumin, whey protein and soy protein for the reduction of dental erosion caused by exposure to acidic compositions having a pH in the range 2.0 to 5.0. | 03-10-2011 |
| 20110117213 | TREATMENT OF ACUTE EXACERBATION OF ASTHMA AND REDUCTION OF LIKELIHOOD OF HOSPITALIZATION OF PATIENTS SUFFERING THEREFROM - The invention provides a method of improving one or more clinical outcomes of an individual experiencing an acute respiratory attack. The acute respiratory attack may include acute reversible bronchospasm, severe acute bronchospasm, or acute exacerbation of asthma. The method includes administering to an individual suffering from an acute respiratory attack an effective amount of bedoradrine or a pharmaceutically acceptable salt thereof in combination with a standard of care (SOC) treatment regimen. | 05-19-2011 |
| 20110129551 | SOLUBLE CD117 (SC-KIT) FOR DIAGNOSIS OF PREECLAMPSIA AND ECLAMPSIA - This disclosure relates to methods of predicting and diagnosing preeclampsia and eclampsia in pregnant subjects. These methods include detecting a decrease of soluble c-kit in a sample obtained from the pregnant subject. A significantly reduced concentration of soluble c-kit in the sample as compared to a gestational age-adjusted control indicates that the pregnant subject will develop or has preeclampsia or eclampsia. | 06-02-2011 |
| 20110183011 | COMPOSITION AND METHOD FOR TOPICAL TREATMENT OF SKIN LESIONS - Disclosed herein is a composition containing a high concentration of PG is unexpectedly capable of quickly killing other bacteria, fungi, and/or virus in vitro that is indicative of its potential high efficacy in treating various skin infection. Embodiments disclosed herein relate to a composition and method for effective topical treatment of inflammatory skin lesions in mammals, comprising of a high concentration of propylene glycol alone, or in combination with an astringent. The PG at high concentrations can be regarded as an extremely effective, safe, topical, universal, microbicide. | 07-28-2011 |
| 20110229587 | Calcium Supplements for the Treatment of Diabetes - Provided herein is a method for treating diabetes, said method comprising administering to a subject with diabetes a composition comprising calcium. | 09-22-2011 |
| 20110250297 | Treatment of Hyperproliferative Disorders Using Cardiac Glycosides - Provided are methods and compositions for treating and preventing hyperproliferative disorders such as psoriasis by administration of a cardiac glycoside alone or in combination locally or systemically with a calciotropic agents and/or a diffusion-limiting component, such a vasoconstrictor or collagen barrier. | 10-13-2011 |
| 20110268820 | USE OF SELECTIVE ESTROGEN RECEPTOR MODULATOR FOR JOINT FUSION AND OTHER REPAIR OR HEALING OF CONNECTIVE TISSUE - Methods for facilitating joint immobilization or fusion using selective estrogen receptor modulator (SERM) such as raloxifene are disclosed. The SERM may be administered systemically or locally. In conjunction with SERM, other therapeutic agents such as calcium, vitamin D, bone morphogenetic protein may be administered simultaneously. The method can similarly be applied to facilitate bone repair, bone healing, and connective tissue healing processes in a patient. | 11-03-2011 |
| 20110280964 | Composition And Method of Treating Hearing Loss - A composition for treating hearing loss includes components that function through different biological mechanisms to provide an additive effect that is equal to or greater than a sum of the effect of the individual components. The composition includes a biologically effective amount of at least one scavenger of singlet oxygen, a donor antioxidant, a third antioxidant, and a vasodilator. A method of treating hearing loss includes the step of internally administering the composition including a biologically effective amount of the at least one scavenger of singlet oxygen, the donor antioxidant, the third antioxidant, and the vasodilator to a mammal within three days of trauma to a middle or inner ear of the mammal. | 11-17-2011 |
| 20110280965 | MATERIALS AND METHODS OF USING CALCIUM FOR REDUCTION OF INFLAMMATION - Nutritional approaches for the control of inflammation can involve the administration of therapeutic amounts of calcium. The administration of appropriate amounts of calcium to an individual results in a reduction in inflammatory processes and markers associated with the inflammatory processes. The therapeutic amount of calcium can be selected to change a level of inflammation in the individual. The approach for reducing inflammation can comprise a step of measuring the C-reactive protein marker level and administering calcium in amounts selected to induce a change in the C-reactive protein level. The calcium can be incorporated into a product with corresponding instructions to induce a desired inflammation reduction. | 11-17-2011 |
| 20110300237 | Protective solutions for organs - Described is a protective solution for avoiding ischemic, storage or ischemia/reperfusion to organs, or to isolated cell systems, or to tissue components after perfusion, surgery, transplantation, or cryopreservation and subsequent reperfusion, which contains alkali ions, and if need be also alkaline earth ions as the electrolyte, a buffer e.g. on a histidine derivation basis, as well as a polyol and/or a saccharide, has an osmolarity of about 290 mosm/l to about 350 mosm/l, as well as a pH value of about 6.8 to about 7.4, and to which hydroxamic acid, and/or one or more hydroxamic acid derivatives are added. | 12-08-2011 |
| 20120058205 | COMPOSITIONS AND TREATMENT REGIMES FOR REDUCING INFLAMMATION, END-ORGAN INJURY, AND/OR SYSTEMIC ENDOTOXEMIA - The invention relates to pharmaceutical compositions and treatment regimes useful in treating one or more of the following conditions: inflammation, kidney disease, eye disease, end-organ injury, systemic endotoxemia, and/or vitamin D resistance. The compositions and treatment regimes are also useful in reducing elevated CRP levels and/or elevated pro-inflammatory cytokines. | 03-08-2012 |
| 20120100229 | Treatment and Prevention of White Matter Injury with KATP Channel Activators - The present invention includes a method of treating or preventing a CNS white matter injury in a patient in need thereof. The invention also includes a method of stimulating proliferation of a CNS cell in a patient in need thereof. | 04-26-2012 |
| 20120107420 | METHODS OF PROGNOSIS IN CHRONIC KIDNEY DISEASE - The present invention relates to methods of prognosing the survival of a diseased subject, particularly a subject with chronic kidney disease (CKD), as well as selecting an end-stage renal disease subject for a kidney transplant. The methods involve detecting an elevated amount of macrophage inhibitory cytokine-1 (MIC-1) in a test body sample from the diseased subject. A method of preventing or reducing the risk of death in a CKD subject which involves removing or inactivating MIC-1 present in the blood, plasma or serum of the subject, is also disclosed. | 05-03-2012 |
| 20120107421 | ESTROGEN RECEPTOR ALLELES THAT ARE PREDICTIVE OF INCREASED SUSCEPTIBILITY TO BONE FRACTURE - In one aspect, the present invention provides methods of determining susceptibility to bone fracture in a mammalian subject, wherein the methods comprise analyzing nucleic acid molecules obtained from the mammalian subject to determine which of the P, p X, and x alleles of the estrogen receptor α gene are present, wherein the presence of a haplotype comprising the p and x alleles is indicative of an increased susceptibility to bone fracture. The present invention also provides kits for determining susceptibility to bone fracture in a mammalian subject. | 05-03-2012 |
| 20120107422 | COMPOSITIONS AND METHOD FOR PREVENTING AND TREATING FIRE BLIGHT - The disclosure relates to compositions for treating and/or preventing fire blight in plants or parts thereof, to their methods of production, to concentrates for producing said compositions and to uses and methods based on said compositions. | 05-03-2012 |
| 20120121730 | PHARMACEUTICAL AND NUTRACEUTICAL COMPOSITIONS FOR TREATING RESPIRATORY DISEASE AND ASSOCIATED PHLEGM - The present invention relates to pharmaceutical compositions comprising dextromethorphan or a physiologically acceptable salt thereof, quercetin, resveratrol, and hesperidin. The invention further relates to nutraceutical or dietary supplement composition comprising a physiologically acceptable salt of magnesium, quercetin, resveratrol, and hesperidin. Further provided are methods for treating respiratory disease in a human subject by substantially eliminating phlegm from the lung through administering to the subject effective amounts of compositions of the invention. | 05-17-2012 |
| 20120148684 | METHODS USEFUL IN THE TREATMENT OF BONE RESORPTION DISEASES - The invention relates to a combined pharmaceutical preparation comprising parathyroid hormone and a bone resorption inhibitor, said preparation being adapted for (a) the administration of parathyroid hormone during a period of approximately 6 to 24 months; (b) after the administration of parathyroid hormone has been terminated, the administration of a bone resorption inhibitor during a period of approximately 12 to 36 months. | 06-14-2012 |
| 20120171307 | Magnesium Compositions and Uses Thereof for Neurological Disorders - A composition for administration to a subject, such as oral administration to a subject, for example, has been provided. Such a composition may comprise at least one magnesium-counter ion compound. A magnesium-counter ion composition described herein may be useful for any of a variety of applications provided herein, such as maintaining, enhancing, and/or improving health, nutrition, and/or another condition of a subject, and/or cognitive, learning, and/or memory function. A magnesium-counter ion composition provided herein may be useful for administration to a subject presenting magnesium deficiency, mild cognitive impairment, Alzheimer's disease, attention deficit hyperactivity disorder, ALS, Parkinson's disease, diabetes, migraine, anxiety disorder, mood disorder, and/or hypertension. A kit, method, and other associated technology are also provided. | 07-05-2012 |
| 20120237617 | USE OF NITRITE SALTS IN TREATING TISSUE DAMAGE - Methods of treating a subject who has an tissue damage or who is at risk for tissue necrosis are disclosed. Also disclosed are methods of treating a subject who has an inflammatory disorder. The methods can include administering to the subject a pharmaceutical composition comprising inorganic nitrite or a pharmaceutically acceptable salt thereof, for a time and in an amount sufficient to reduce the tissue damage. The subject can be diagnosed as having a medical condition that results tissue damage, for example, diabetes, peripheral artery disease, cardiovascular disease, defective wound healing, arthritis, inflammatory bowel disease, ischemia, or a bacterial infection, e.g., Group A staphylococcal infection. The methods can include the step of monitoring the course of treatment. | 09-20-2012 |
| 20120244232 | BLACK BEAR PARATHYROID HORMONE AND METHODS OF USING BLACK BEAR PARATHYROID HORMONE - Black bear parathyroid hormone (PTH) and functional fragments thereof are provided. Also provided are methods of using black bear PTH and functional fragments for increasing cAMP in a bone-forming cell; reducing apoptosis in a bone-forming cell; decreasing the ratio of expression levels of Bax protein to Bcl-2 protein in a bone-forming cell; increasing the expression level of one or more of a bone matrix protein, a transcriptional activator, or a transcriptional regulator in a bone-forming cell; enhancing bone mineral density, increasing bone mass, decreasing bone loss, or reducing the incidence of bone fractures, or any combination thereof, in a subject; also provided are antibodies directed against black bear parathyroid hormone (PTH) and functional fragments thereof. | 09-27-2012 |
| 20120251632 | TREATMENT OF ACUTE EXACERBATION OF ASTHMA AND REDUCTION OF LIKELIHOOD OF HOSPITALIZATION OF PATIENTS SUFFERING THEREFROM - The invention provides a method of improving one or more clinical outcomes of an individual experiencing an acute respiratory attack. The acute respiratory attack may include acute reversible bronchospasm, severe acute bronchospasm, or acute exacerbation of asthma. The method includes administering to an individual suffering from an acute respiratory attack an effective amount of bedoradrine or a pharmaceutically acceptable salt thereof in combination with a standard of care (SOC) treatment regimen. | 10-04-2012 |
| 20120282352 | PHOSPHATE-BINDING MAGNESIUM SALTS AND USES THEREOF - The present invention provides, among other things, compositions and methods suitable for the treatment of hyperphosphatemia based on phosphate-binding magnesium salts. In some embodiments, the present invention provides compositions and methods suitable for the treatment of hyperphosphatemia based on the combination of phosphate-binding magnesium and calcium salts. | 11-08-2012 |
| 20120315342 | EPITHELIAL CELL-CELL ADHESION ENHANCER, AND AMELIORATING, THERAPEUTIC OR PROPHYLACTIC AGENT FOR ALLERGIC DISEASES USING SAME - Disclosed is a composition containing a specific oligosaccharide and a bivalent metal cation, which exhibits an effect on the amelioration, treatment or prevention of allergy or topical inflammatory reactions in an extremely safe and effective manner compared to synthetic oral steroid medicines in spite of a fact that the composition contains components that are generally familiar as a food or an ion occurring in living bodies and have no toxicity against living bodies when used at physiological concentrations. Specifically disclosed is a cell-cell adhesion enhancer in epithelial cells, which comprises 1-kestose and/or nystose and a bivalent metal cation as active ingredients. The enhancer can prevent the disruption of an epithelial cell-cell tight junction protein that causes the invasion of an allergen into the body, can repair the epithelial cell-cell tight junction protein or promote the formation of the epithelial cell-cell tight junction protein, whereby the epithelial cell-cell adhesion can be enhanced and the effective amelioration, treatment and prevention of allergic symptoms can be achieved. | 12-13-2012 |
| 20120328717 | PHARMACEUTICAL KIT FOR TREATING NEURONAL DAMAGES - A pharmaceutical kit for treating neuronal damages is disclosed. The pharmaceutical composition of the present invention comprises: a first pharmaceutical composition comprising a first effective amount of a Mg | 12-27-2012 |
| 20130064903 | RHEUMATIOD ARTHRITIS CURE - A cause and cure for Rheumatiod Arthritis which includes the body becoming acid and retaining fluids as a means of diluting said acid. Calcium with adequate vitamin D for absorption neutralizes said acid and brings the body back in balance. In addition, an overabundance of the mineral potassium slows the removal of fluid from the body causing fluid to be retained and stored in the joints and soft tissues. Said storage of retained fluid is what causes the symptoms of rheumatoid arthritis and related illnesses and even fibromyalgia and headaches. Joints become swollen and prolonged inflammation results in joint deformity. Said abundance of potassium also causes an imbalance of other minerals in the body, especially sodium, resulting in dehydration. Water and balanced electrolytes must be added to correct the problem. | 03-14-2013 |
| 20130078320 | COMPOSITION FOR TREATING HEARING LOSS - A composition to be administered to a mammal for treating hearing loss is disclosed herein. The composition consists essentially of a biologically effective amount of vitamin A, vitamin C, vitamin E, and a vasodilator comprising magnesium. The composition optionally includes a withanolide and/or resveratrol. The vitamin A, vitamin C, vitamin E, and the vasodilator comprising magnesium provides an additive effect that is equal to or greater than a sum of the effects of the individual components. | 03-28-2013 |
| 20130101685 | METHOD FOR MANUFACTURING CALCIUM SILICATE BASED COMPOSITION - Provided is a method that enables a calcium silicate-based material to be produced more efficiently. The method of producing a calcium silicate-based material comprises: (1) a step of obtaining a reaction product by reacting raw materials containing a calcium component, a silicon component and an aluminum component in an aqueous medium; and (2) a step of forming calcium silicate by subjecting the reaction product to hydrothermal treatment. | 04-25-2013 |
| 20130142888 | N-ACETYL-DL-LEUCINE, NEUROPROTECTIVE AND RETINOPROTECTIVE MEDICAMENT - The invention relates to a medicament, the active principle of which is a leucine and, for example, a N-ACETYL-DL-LEUCINE. It can be applied to the prevention and/or treatment of eye diseases or disorders and especially of hereditary dystrophies of the retina, glaucomatous neuropathy, glaucoma, macular degeneration, myopia, presbyopia, hypermetropia, astigmatism, all the ophtalmologic diseases or disorders inducing a decrease of visual function and/or age-related physiological vision decline. | 06-06-2013 |
| 20130171269 | COMPOSITIONS AND METHODS FOR ALLEVIATING SYMPTOMS ASSOCIATED WITH PREMENSTRUAL SYNDROME AND PREMENSTRUAL DYSPHORIC DISORDER - The present invention discloses pharmaceutical/nutritional compositions and methods for alleviating symptoms associated with premenstrual syndrome (PMS) and premenstrual dysphoric disorder (PMDD). The pharmaceutical/nutritional compositions include at least 2% (w/w) phosphatidyl-L-serine, or salts thereof, out of a total effective composition, as a first effective ingredient; and a suitable amount of at least one bio-available form of magnesium as a second effective ingredient. Preferably, the bio-available form of magnesium is magnesium oxide, magnesium citrate, magnesium hydroxide, magnesium stearate, or a magnesium salt of the phosphatidyl-L-serine. Preferably, the composition further includes a pharmaceutical or nutritional excipient. Preferably, the total effective composition is administrable in a multi-part regimen. Preferably, the total effective composition is administrable by intravenous or oral delivery. Preferably, the pharmaceutical/nutritional composition further includes at least 2% (w/w) phosphatidic acid, or salts thereof, out of the total effective composition, as a first effective ingredient. | 07-04-2013 |
| 20130171270 | METHOD FOR MANUFACTURING CALCIUM SILICATE BASED COMPOSITION - Provided is a method that enables a calcium silicate-based material to be produced more efficiently. The method of producing a calcium silicate-based material comprises: ( | 07-04-2013 |
| 20130189377 | COMPOSITIONS - The present invention concerns solid compressed oral pharmaceutical compositions comprising a mixture of at least two sulphate salts selected from the group consisting of sodium, potassium and magnesium for use, in particular, in cleansing the colon or treating faecal impaction, constipation, faecal retention, intestinal gas and cramping, or flatulence in a mammal. Methods of producing such compositions are also disclosed. | 07-25-2013 |
| 20130259956 | Pharmaceutical Kit for Treating Neuronal Damages - A pharmaceutical kit for treating neuronal damages is disclosed. The pharmaceutical composition of the present invention comprises: a first pharmaceutical composition comprising a first effective amount of a Mg | 10-03-2013 |
| 20130295202 | USE OF SELECTIVE ESTROGEN RECEPTOR MODULATOR FOR JOINT FUSION AND OTHER REPAIR OR HEALING OF CONNECTIVE TISSUE - Methods for facilitating joint immobilization or fusion using selective estrogen receptor modulator (SERM) such as raloxifene are disclosed. The SERM may be administered systemically or locally. In conjunction with SERM, other therapeutic agents such as calcium, vitamin D, bone morphogenetic protein may be administered simultaneously. The method can similarly be applied to facilitate bone repair, bone healing, and connective tissue healing processes in a patient. | 11-07-2013 |
| 20130295203 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEUROPSYCHIATRIC DISORDERS - Methods and compositions are disclosed to treat neuropsychiatric disorders based upon a new framework of diagnosis. Axis I biomarkers include genes related to prefrontal dopamine synthesis and/or dopamine degradation. Axis II includes genes related to re uptake of dopamine, norepinephrine and serotonin and autonomic hyperactivity. Axis III includes genes relates to impairments in inflammatory pathways, glutamate neurotransmission and/or neurotrophic factors. Axis IV includes genes related to glutamate reuptake and predisposition to addictive behavior, and obsessive compulsions. | 11-07-2013 |
| 20130302444 | Method for Treating Hearing Loss - A method of treating hearing loss includes the step administering a composition to the mammal, wherein the composition consists essentially of a biologically effective amount of vitamin A, vitamin E, vitamin C, a vasodilator comprising magnesium, and, optionally, a withanolide, and/or resveratrol. | 11-14-2013 |
| 20130330423 | COMPOSITION TO INCREASE JOINT AND/OR POSTURAL STABILITY - The invention is directed to a composition for the use to increase joint stability or postural stability, wherein said composition comprises branched chain amino acids. It is further directed to the use of branched chain amino acids for the preparation of a food supplement or medicament for the prophylaxis and/or treatment of joint and/or postural instability. | 12-12-2013 |
| 20140023729 | Nutritional supplement for disinhibiting therapy of psychiatric patients - The present invention is a composition and methods of administering the composition to improve a person's mental and physical health by increasing energy levels, motivation, willingness to communicate, appetite, and memory. The composition may be used to treat mental conditions by improving a person's wiliness and ability to communicate. The increase in appetite effect of the composition may be used to treat eating disorders. The composition comprises a carbohydrate, one or more NAD+/NADP+ producing vitamins, poly-sulfurous chelating agents, vasodilating salts, coenzyme-A producing vitamins, antioxidants, kinins, and biological energy sources. | 01-23-2014 |
| 20140030361 | IMPLANT WITH SURFACE WITH CALCIUM, AND METHODS FOR MODIFYING THE SURFACE OF AN IMPLANT TO PROVIDE SAID SURFACE WITH CALCIUM - The invention relates to an implant for the human or animal body, which on its outer surface comprises at least one calcium salt that is soluble in a polar liquid. The invention also refers to various methods for the preparation of the preceding implant. The calcium ions contained on the surface of the implant provide said surface with four chemically and biologically advantageous properties: hydrophilicity, protection against atmospheric contamination, a pro-coagulant property and a pro-mineralising property. | 01-30-2014 |
| 20140044803 | METHOD OF USING FLIBANSERIN FOR NEUROPROTECTION - The present invention relates to the use of 1-[2-(4-(3-trifluoromethyl-phenyl)piperazin-1-yl)ethyl]-2,3-dihydro-1H-benzimidazol-2-one, optionally in the form of its pharmaceutically acceptable acid addition salts and optionally in the form of its hydrates or solvates, for preparing a pharmaceutical composition with a neuroprotective activity. | 02-13-2014 |
| 20140056999 | TREATMENT OF ACUTE EXACERBATION OF ASTHMA AND REDUCTION OF LIKELIHOOD OF HOSPITALIZATION OF PATIENTS SUFFERING THEREFROM - The invention provides a method of improving one or more clinical outcomes of an individual experiencing an acute respiratory attack. The acute respiratory attack may include acute reversible bronchospasm, severe acute bronchospasm, or acute exacerbation of asthma. The method includes administering to an individual suffering from an acute respiratory attack an effective amount of bedoradrine or a pharmaceutically acceptable salt thereof in combination with a standard of care (SOC) treatment regimen. | 02-27-2014 |
| 20140065245 | METHOD FOR PREPARING DIETARY SUPPLEMENTS - A novel dietary supplement and methods for manufacturing the said dietary supplement are disclosed for promoting healthy cartilages, connective tissues and bones. The dietary supplement of the present invention comprises glucosamine hydrochloride, collagen, and other dietary ingredients. Some ingredients of the dietary supplement of the present invention help to maintain the functions of cartilages, connective tissues and bones. Some ingredients of the dietary supplement of the present invention also exhibit anti-inflammatory properties. Overall, these ingredients of the dietary supplement are beneficial to the health of human and other animals. | 03-06-2014 |
| 20140065246 | INTRACELLULAR CALCIUM MODULATION FOR CANCER TREATMENT - Tumor cells exhibit consistent abnormalities in calcium regulation. The present disclosure teaches methods by which such differences are exploited to induce Apoptosis selectively in tumor/cancer cells while sparing normal cells. These methods are based upon employing drugs that, acting in synergistic combinations, trigger selective killing of malignant cells. Since the invention is based upon fundamental cell cycle requirements, to the extent that calcium handling abnormalities are a general characteristic of the malignant state, the methods presented here are widely applicable regardless of tissue of origin and degree of cellular de-differentiation. | 03-06-2014 |
| 20140072657 | NOVEL PHARMACEUTICAL FORMULATION - The present invention provides novel compositions comprising chitosan and vitamin D or chlorhexidin and vitamin D for the treatment of mucosal and epithelial wounds and for the treatment or prevention of oral, mucosal or dermal infections or inflammations. | 03-13-2014 |
| 20140099387 | COMPOSITIONS AND METHODS FOR TREATMENT - The present invention provides compounds and methods for the treatment of LFA-1 mediated diseases. In particular, LFA-1 antagonists are described herein and these antagonists are used in the treatment of LFA-1 mediated diseases. One aspect of the invention provides for diagnosis of an LFA-1 mediated disease and administration of a LFA-1 antagonist, after the patient is diagnosed with a LFA-1 mediated disease. In some embodiments, the LFA-1 mediated diseases treated are dry eye disorders. Also provided herein are methods for identifying compounds which are LFA-1 antagonists. | 04-10-2014 |
| 20140106008 | GLYCEROL COMPOSITIONS AND SOLUTIONS - The invention discloses the use of a treatment composition for preventing, or reducing, the production of contaminants selected from microorganisms and microorganism-produced toxins by contacting the substrate with the composition. The composition comprises a water glycerol mixture and calcium hydroxide in which the percentage by mass of glycerol in the water glycerol mixture is between 5% and 95%, at least some of the calcium hydroxide is dissolved in the water glycerol mixture and the concentration of the dissolved calcium hydroxide in the water glycerol mixture is at least 1.5 times higher than the maximum concentration of dissolved calcium hydroxide which can be obtained in water alone, thereby preventing or reducing the production of the contaminants. The extent of the prevention or reduction is at least 1.5 times more than the corresponding prevention or reduction produced by a treatment composition comprising water and calcium hydroxide only. | 04-17-2014 |
| 20140127328 | METHODS AND COMPOSITIONS FOR TREATING ANXIETY DISORDERS OR SYMPTOMS THEREOF - The present invention relates to methods and compositions for reducing distress dysfunction, including emotional and physical distress. The invention entails co-administration of at least one Receptor Switcher and at least one Endorphin Enhancer. Additionally, at least one Synergistic Enhance and/or at least one Exogenous Opioid are also administered to enhance or prolong the therapeutic effects. | 05-08-2014 |
| 20140134279 | DRINK FOR THE RAPID REPLACEMENT OF CALCIUM IONS IN THE BLOOD STREAM - The present invention relates to a beverage that provides rapid uptake of calcium ions into the blood stream in less than ten minutes. | 05-15-2014 |
| 20140141102 | TRIMEGESTONE (TMG) FOR TREATMENT OF PRETERM BIRTH - As disclosed herein, novel compositions including steroid hormones, such as trimegestone (TMG) and progesterone (P4), provide treatments for term and preterm labor with significant effects on the delay of delivery. Delay and block of delivery occurs when both P4 and TMG are administered late in gestation in pregnant rat and guinea pig animal models. TMG exhibits remarkable drug efficacy, achieving the same inhibition as P4, but at much lower doses. These hereto unknown effects of TMG on the processes of cervical ripening and uterine contraction provide a novel approach for extending pregnancy term, including reducing a likelihood of preterm and/or term labor, along with improved methods of administration. Other diseases and/or conditions may be treated with TMG, such as dysmenorrhea or luteal insufficiency for sustaining pregnancy. | 05-22-2014 |
| 20140147519 | Migraine Treatment - A migraine treatment formulation is designed to be administered upon onset of migraine symptoms. The migraine treatment formulation is able to reduce the nausea and pain associated with a migraine headache through a pharmaceutical composition that carries a reduced chance of causing digestive discomfort. The treatment formulation accomplishes this through a combination of organic and inorganic agents, administered orally, that are optimized for absorption through the mucosal membrane and the lining of the stomach. The higher absorption rate of the active constituents quickly alleviates the various symptoms associated with a migraine headache while preventing unabsorbed constituents from causing digestive issues. | 05-29-2014 |
| 20140147520 | Water-based Personal Moisturizers and Lubricants, in Particular Vaginal Lubricants, and Uses Thereof - There is a need for water-based sperm- and egg-friendly vaginal lubricant. We describe novel water-based nature-friendly personal moisturizers and lubricants that relieve vaginal dryness. In addition to being non-spermicidal, sperm- and egg-friendly and biological-fluids mimicking, these personal moisturizers and lubricants also enhance sperm survival and motility, promote binding of sperm to eggs and facilitate the process of fertilization. Novel articles, and systems as well as methods of preparation and use of the novel compositions are also provided. | 05-29-2014 |
| 20140154341 | BIORESORBABLE METAL ALLOY AND IMPLANTS MADE OF SAME - Disclosed herein is a non-toxic, bioresorbable, magnesium based alloy for use in production of implants. Specifically exemplified herein are alloy embodiments useful for orthopedic implants. Also disclosed are alloy materials that incorporate magnesium, calcium and strontium. | 06-05-2014 |
| 20140186471 | COMPOSITION FOR INHIBITION OF CATHEPSIN K - The present invention relates to the a method of inhibiting bone resorption in a mammal in need thereof with an oral pharmaceutical composition comprising a cathepsin K inhibitor, or a pharmaceutically acceptable salt thereof, or a mixture thereof, according to a continuous schedule having a dosage interval of once weekly, biweekly, twice monthly or once monthly. | 07-03-2014 |
| 20140205684 | MACROPHAGE INHIBITORY CYTOKINE-1 (MIC-1) AS A PROGNOSTIC MARKER IN CHRONIC KIDNEY DISEASE - The present invention relates to methods of prognosing the survival of a diseased subject, particularly a subject with chronic kidney disease (CKD), as well as selecting an end-stage renal disease subject for a kidney transplant. The methods involve detecting an elevated amount of macrophage inhibitory cytokine-1 (MIC-1) in a test body sample from the diseased subject. A method of preventing or reducing the risk of death in a CKD subject which involves removing or inactivating MIC-1 present in the blood, plasma or serum of the subject, is also disclosed. | 07-24-2014 |
| 20140255514 | DEFOAMER USEFUL IN A PERACID COMPOSITION WITH ANIONIC SURFACTANTS - Low foaming, highly acidic peroxycarboxylic acid sanitizing compositions are disclosed as having both improved antimicrobial efficacy in comparison to conventional peroxyoctanoic acid and peroxyacetic acid compositions for sanitizing applications. The compositions include a combination of a low-foaming surfactant and an aluminum sulfate (or other metal salt) defoaming agent that is compatible with the highly acidic peroxycarboxylic acid sanitizing compositions. In particular, the sanitizing peroxycarboxylic acid compositions are also low odor and low/no VOC dual functioning acid wash and sanitizing compositions. | 09-11-2014 |
| 20140255515 | LIQUID COMPOSITIONS OF CALCIUM ACETATE - The invention relates to an aqueous liquid composition of calcium acetate, sweetener, and taste masking agent. Also provided is a method for binding phosphorus within the gastrointestinal tract of an individual by administering to the individual an aqueous solution of at least calcium acetate. | 09-11-2014 |
| 20140370124 | MULTI-PURPOSE ANTI-ITCH TREATMENT - There is disclosed a formulation of a transdermal skin treatment effective in inhibition of itch sensation. In an embodiment, the formulation includes a solvent mixture of alcohols, glycols and water combined to provide a solubility parameter between 20 Pa | 12-18-2014 |
| 20150010651 | Compositions and methods for the treatment of wounds - The present invention is directed to a wound composition comprising an effective amount of phenyloin and an effective amount of vitamin C. The present invention is further directed to a method of treating a wound in a patient comprising administering an effective amount of phenyloin and an effective amount of vitamin C to the wound. | 01-08-2015 |
| 20150017265 | METHODS OF MODIFYING MYOCARDIAL INFARCTION EXPANSION - A bioscaffolding can be formed within a post-myocardial infarct region sufficient to cause attenuation of a rate of myocardial infarct expansion. A bioscaffolding may further be formed in the post-myocardial infarct region to cause an increase in posterior left ventricular wall thickness. The gel or bioscaffolding can be formed from a mixture of gel components of different gelation systems. For example, a bioscaffolding can be formed by mixing at least two different components of at least two different two-component gelation systems to form a first mixture and by mixing at least two different components (other than the components that make up the first mixture) of the at least two different two-component gelation systems to form a second mixture. | 01-15-2015 |
| 20150017266 | Compositions and Methods for Relieving Symptoms of Rheumatoid Arthritis and Related Illnesses - Compositions and methods for relieving symptoms of rheumatoid arthritis (RA) and related illnesses are disclosed. It appears that the primary cause of RA is a sensitivity or hypersensitivity to potassium and/or vitamin C, or too much potassium and/or vitamin C in the diet. The effects of potassium and vitamin C on the body must be modified to relieve the symptoms of RA and related illnesses. It appears that magnesium does not cause the inflammation, but appears that it exacerbates the problem. It appears that calcium and vitamin D intake, possibly in combination with the reduced or no intake of potassium and/or vitamin C, may also help to relieve the symptoms of RA and related illnesses. | 01-15-2015 |
| 20150024068 | DIALYSIS COMPOSITION COMPRISING CITRATE, CALCIUM AND MAGNESIUM - Dialysis fluid compositions including 0.5 to 3 mM citrate, 1 to 5 mM total calcium, and 0 to 1.5 mM total magnesium. These dialysis fluid compositions include 0.10 to 0.2 mM more total calcium per 1 mM citrate within the dialysis fluid as compared to the calcium concentration ordinarily prescribed for a non-citrate containing dialysis fluid. | 01-22-2015 |
| 20150024069 | COMPOSITIONS AND METHODS FOR TREATMENT OF HEMORRHAGE - Methods of treating hemorrhage are provided, comprising diagnosing one or more hemorrhaging or potentially hemorrhaging vessels in a patient and administering to the patient a therapeutically effective amount of a composition comprising a vessel closing compound at a concentration between about 0.1% and about 45%. The vessel closing compound may comprise a polymer with hydrophilic properties, such as polyethylene glycol (PEG). The composition may also comprise one or more active agent such as a blood flow modifier with a potential to form ionic bonds with the vessel closing agent. | 01-22-2015 |
| 20150030703 | COMPOSITIONS AND METHODS FOR PREFERENTIAL DISTRIBUTION OF ACTIVE AGENTS TO INJURY SITES - Compositions are provided for preferential distribution of active agents to injury sites. Such compositions may comprise a ligand with hydrophilic properties and one or more active agents, such as compounds comprising hydrophilic metal ions. Because the delivery ligand and the active agent are specifically selected so the interactions between them are mainly of an ionic nature so that binding of the active agent to the delivery ligand and release of the active agent into the target site are not dependent on enzymatic activity. Methods of using such compositions are also disclosed. | 01-29-2015 |
| 20150079201 | COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES - Compositions comprising electro-activated aqueous solutions and methods for the prevention and treatment of dysfunctional cardiovascular conditions are provided. | 03-19-2015 |
| 20150140128 | COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES - Compositions comprising electro-activated aqueous solutions and methods for the prevention and treatment of dysfunctional cardiovascular conditions are provided. | 05-21-2015 |
| 20150140129 | COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES - Compositions comprising electro-activated aqueous solutions and methods for the prevention and treatment of dysfunctional cardiovascular conditions are provided. | 05-21-2015 |
| 20150290241 | COMPOSITION FOR PREVENTING, ALLEVIATING OR TREATING CONSTIPATION, CONTAINING HIGH HARDNESS MINERAL WATER PREPARED FROM DEEP OCEAN WATER OR DESALINATED GROUNDWATER - The present invention relates to a functional composition for preventing, alleviating or treating constipation, containing high hardness mineral water prepared from deep ocean water or desalinated groundwater, and a method therefor. The present invention contains high hardness mineral water prepared from deep ocean water or desalinated groundwater as an active ingredient so as to be safe to the human body, and thus can be useful for treating constipation of a cancer patient and constipation of a regular person. | 10-15-2015 |
| 20150313812 | Matte Cosmetic Compositions - The present invention relates generally to cosmetic compositions that impart a matte finish to human integuments. More specifically, the invention relates to lip cosmetics that impart a matte finish. | 11-05-2015 |
| 20150320814 | NUTRACEUTICAL FORMULATION FOR TREATMENT OF ANXIETY AND DEPRESSION - Disclosed are compositions of matter useful for treating anxiety and depression. In one embodiment a nutraceutical composition is administered to a patient in need of said composition comprising of the following combination of ingredients: niacin, magnesium, ashwagandha, passionflower, skullcap, St. John's Wort, gamma aminobutryic acid, chamomile, and L-theanine | 11-12-2015 |
| 20150335599 | HIGH-LOADING, CONTROLLED-RELEASE MAGNESIUM ORAL DOSAGE FORMS AND METHODS FOR MAKING AND USING SAME - Disclosed are high loading, controlled-release dosage forms for oral administration of magnesium salts. For example, an oral dosage form can comprise from about 80% to about 95% magnesium lactate and one or more components. As another example, an oral dosage form can comprise at least about 50% magnesium salt and exhibit a controlled release dissolution profile. Also disclosed are methods for making controlled release dosage forms for oral administration of a therapeutically effective amount of magnesium salt to a mammal. Also disclosed are methods for treating a disorder characterized by magnesium deficiency and methods for preventing or alleviating low magnesium levels. | 11-26-2015 |
| 20150374659 | Composition and Method for Treating Tinnitus - A method of treating tinnitus includes the step administering a composition to the mammal, wherein the composition consists essentially of a biologically effective amount of vitamin A, vitamin E, vitamin C, a vasodilator comprising magnesium, and, optionally, a withanolide, and/or resveratrol. | 12-31-2015 |
| 20160008516 | POLY(LACTIC-CO-GLYCOLIC ACID (PLGA) COMPOSITES WITH MAGNESIUM WIRES ENHANCED NETWORKING OF PRIMARY NEURONS | 01-14-2016 |
| 20160022655 | COMPOSITIONS AND METHODS FOR PREVENTING INFECTION OF A WOUND AND FOR ADVANCING THE HEALING PROCESS - The present disclosure relates to compositions and methods that are effective in controlling and preventing bacterial, viral and fungal infections in the living tissue of plants, humans and animals, and in advancing the healing process for wounds to that tissue. The disclosed compositions comprise a biocidal system, a pH buffer, and one or more of a surfactant, a cellular energy supplement, an inflammation reducer, a clotting agent, an electrolytic system, a lattice forming system, and for plants a fungicide, all in an aqueous composition. | 01-28-2016 |
| 20160030474 | Brain, Spinal and Nerve Injury Treatment - A treatment for brain, spinal and nerve injury comprising use of a substance P receptor antagonist optionally in combination with a magnesium compound. There is also provided a formulation for use in this treatment comprising a substance P receptor antagonist and a magnesium compound. | 02-04-2016 |
| 20160038535 | COMPOSITIONS AND TREATMENT REGIMES FOR REDUCING INFLAMMATION, END-ORGAN INJURY, AND/OR SYSTEMIC ENDOTOXEMIA - The invention relates to pharmaceutical compositions and treatment regimes useful in treating one or more of the following conditions: inflammation, kidney disease, eye disease, end-organ injury, systemic endotoxemia, and/or vitamin D resistance. The compositions and treatment regimes are also useful in reducing elevated CRP levels and/or elevated pro-inflammatory cytokines | 02-11-2016 |
| 20160054330 | BIOMARKERS FOR HYPERTENSIVE DISORDERS OF PREGNANCY - The application discloses new biomarkers for hypertensive disorders of pregnancy and particularly preeclampsia; methods for the diagnosis, prediction, prognosis and/or monitoring said disorders based on measuring said biomarkers; and kits and devices for measuring said biomarker and/or performing said methods. | 02-25-2016 |
| 20160058060 | FOOD SALT PRODUCT - The invention provides a multi-component homogenous co-crystallized low sodium salt product for food and pharmaceutical use. The salt product of the invention is essentially segregation-free, has low hygroscopicity and is free-flowing. It has good microbial depression properties and good taste. It supplies the functionality of salt (NaCl) in processed foods and it also maintains the microbial safety, nutritional value and taste. The salt product of the invention includes an alkaline and alkaline earth metal chloride component and an ammonium chloride component. An alkaline metal is potassium (K), and optionally also sodium (Na). An alkaline earth metal is Magnesium (Mg) or Magnesium (Mg) and Calcium (Ca) having the sum of the molar ratios 1. The invention provides also a process to produce the salt products of the invention. | 03-03-2016 |
| 20160082041 | WEIGHT REDUCING COMPOSITION - The invention relates to soft drink industry, in particular, to dietetic nutrition. The inventive weight reducing composition comprises 0.01-10 mg/l of sodium and 25-150 mg/l of magnesium, the rest being water. Said composition (drinking water) makes it possible to reduce weight without altering the usual eating habits. In addition, consumption of said drinking water results in reduction of weight by 1.2-2.9 kg. | 03-24-2016 |
| 20160143290 | METHOD OF CONTROLLING WATER SURFACE INHABITING PESTS - The present invention discloses a method for controlling surface-inhabiting pests in an aquatic system, in particular cyanobacteria and harmful algal blooms (HABs), comprising spreading on the surface of the aquatic system a buoyant composition comprising a water disinfectant, preferably an oxidizing compound, and a floating agent. The invention further relates to compositions and methods for their preparation and use. | 05-26-2016 |
| 20160151414 | Pure nano clacium powder and method | 06-02-2016 |
| 20160158280 | A METHOD FOR ORGAN ARREST, PROTECTION AND PRESERVATION AND REDUCING TISSUE INJURY - The invention relates to compositions and methods for Inducing organ arrest, maintaining arrest and reanimating in a subject that has suffered a life threatening disease or injury; preparing, harvesting, storing organs, tissues and cells; reducing the harmful effects of at least one of anaesthesia, surgery, clinical intervention, and cardiopulmonary bypass on injuring the tissues, organs and cells of a subject; or reducing the harmful effects of surgery or clinical intervention on injuring the organs and brain in the whole body of a subject. The composition comprises (i) a compound selected from at least one of a potassium channel opener, a potassium channel agonist and an adenosine receptor agonist; (ii) an antiarrhythmic agent or a local anaesthetic; and (iii) citrate. | 06-09-2016 |
| 20160166568 | METHODS AND COMPOSITIONS FOR CORRECTION OF ORGAN DYSFUNCTION | 06-16-2016 |
| 20160166598 | A METHOD FOR TREATING INFECTION, SEPSIS AND INJURY | 06-16-2016 |
| 20160175349 | BRAIN FUNCTION-IMPROVING COMPOSITION | 06-23-2016 |
| 20160192658 | HYDROGEN-CONTAINING ANTIMICROBIAL AGENT | 07-07-2016 |
| 20170232360 | ALKALINE EARTH METAL SALTS | 08-17-2017 |
| 20190142046 | FUNCTIONALLY REINFORCED DESALTED NUTRITIONAL COMPOSITIONS FROM HALOPHYTES AND PREPARATION METHOD THEREOF | 05-16-2019 |
| 20190144796 | INTERCALATED BLEACH COMPOSITIONS, RELATED METHODS OF MANUFACTURE AND USE | 05-16-2019 |
